A Differentiated Approach to Investing with Growth-Oriented Healthcare Businesses

David Friedman, a Partner with Gauge Capital, a Dallas-based private equity firm with over $2 billion in assets under management, highlights his background, Gauge’s healthcare focus areas for new platform investments in 2022, and their approach to partnering with [growing] businesses.

David speaks to the art and science of working within the healthcare sector. It’s a complicated space as it is both the largest and fastest-growing sector within the economy. With evolving technology there is a constant opportunity to identify ways to focus on improvements while reducing costs. One thing is likely certain; the healthcare system we know today is going to look very different in the next 10 to 20 years.

In speaking about what makes Gauge Capital different from other investment firms, David clearly conveys what he believes to be the primary differentiator:

“If I was going to point us to one thing that I think makes Gauge different is really our uncompromising focus on alignment.”

Within the private equity space, most firms commit to providing a small portion of the investment from within and the rest of the money comes from outside investors. This allows firms to take minimal risk yet still getting meaningful upside.

At Gauge Capital, the senior investment team represents more than 20% of the Fund Capital in the latest fund. Furthermore, the average management ownership is more than 30% post-close creating strong alignment among Gauge and their partners.

“That just creates the alignment so that all of us are very focused on creating long-term value that drives the business forward,” stated David Friedman.

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More
Immuno-Oncology
Shaping the Future of Cancer Care Through Immuno-Oncology
April 19, 2025

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…

Read More